Roivant Sciences Ltd.
ROIV
$11.31
-$0.05-0.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 58.20M | 113.56M | 5.04B | 5.04B | 4.65B |
| Total Depreciation and Amortization | 14.99M | 20.62M | 21.20M | 21.20M | 22.15M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -546.22M | -524.57M | -5.53B | -5.53B | -5.24B |
| Change in Net Operating Assets | -99.62M | -118.15M | -43.85M | -43.85M | -7.52M |
| Cash from Operations | -572.65M | -508.54M | -511.74M | -708.17M | -765.27M |
| Capital Expenditure | -3.60M | -3.14M | -1.67M | -1.67M | -1.11M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 229.36M | 153.63M | 5.23B | 5.23B | 5.23B |
| Other Investing Activities | 1.30B | 309.55M | 8.08M | 8.08M | 8.59M |
| Cash from Investing | 1.53B | 460.04M | 5.24B | 5.20B | 5.20B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -50.92M | -58.59M | -17.16M | -17.16M | -23.14M |
| Issuance of Common Stock | 43.36M | 34.04M | 14.81M | 14.81M | 33.56M |
| Repurchase of Common Stock | -1.22B | -941.65M | -692.99M | -692.99M | -37.67M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 112.78M | 0.00 | 238.73M | 238.73M | 238.73M |
| Cash from Financing | -1.11B | -966.19M | -456.60M | -248.73M | 419.36M |
| Foreign Exchange rate Adjustments | -4.30M | -4.66M | -553.00K | -553.00K | 2.07M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.36M | -1.02B | 4.27B | 4.24B | 4.86B |